Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy
Jayaprakash Sahoo1★, Sadishkumar Kamalanathan1, Muthupillai Vivekanandan1, Rathinam Palamalai Swaminathan2★ Corresponding author
- 1Departments of Endocrinology and Metabolism, Institute of Postgraduate Medical Education and Research, Puducherry, India.
- 2Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
CORRESPONDENCE
Jayaprakash Sahoo
Departments of Endocrinology and Metabolism, Institute of Postgraduate Medical Education and Research, Puducherry, India.
Received: 26-09-2014; Revised: 18-11-2014; Accepted: 24-01-2015.
Volume 6, Issue 3 · pp. 172–174 · PUBLISHED 2015 · DOI: 10.4103/0976-500X.162016
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Dipeptidyl peptidase‑4 (DPP‑4) inhibitors are a new class of anti‑diabetic drugs. They control both fasting and postprandial hyperglycemia by inhibiting degradation of incretin hormones, such as, glucagon‑like peptide‑1(GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). Sitagliptin is the first DPP‑4 inhibitor to be marketed in India. In addition to its glucose lowering effect, it also suppresses immunity resulting in various infections in a diabetes patient. Here, we describe the simultaneous development of two infections (acalculous pyelonephritis and cholecystitis) in a postmenopausal female patient, well‑controlled on sitagliptin‑based anti‑diabetic therapy.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Sahoo, J., Kamalanathan, S., Vivekanandan, M., & Swaminathan, R. P. (2015). Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy. Journal of Pharmacology and Pharmacotherapeutics, 6(3), 172–174. https://doi.org/10.4103/0976-500X.162016